West Asia Conflict Puts Pressure on India's Medicine Prices

India’s medicine prices are under pressure as the ongoing West Asia conflict begins to disrupt the pharmaceutical supply chain, raising concerns across the healthcare sector.

Industry experts warn that medicine prices could rise soon due to a sharp increase in the cost of raw materials and logistics linked to the conflict.

India relies heavily on imported active pharmaceutical ingredients (APIs) and key chemicals, many of which are connected to supply routes passing through or influenced by West Asia.

With tensions escalating, shipping routes have become unstable, leading to delays and higher freight charges. At the same time, rising crude oil prices are pushing up production and transportation costs, further squeezing manufacturers.

Also Read: World Liver Day 2026 Raises Concern Over Liver Damage

Pharmaceutical companies have reported that prices of essential raw materials have surged significantly in recent weeks. In some cases, costs have jumped between 30 percent and 100 percent, making it difficult for companies to maintain current pricing levels. The impact is expected to be felt across commonly used drugs, including those for diabetes, cancer, and hypertension.

Despite the rising pressure, most companies have not yet passed on the full cost to consumers. However, industry insiders suggest that this may change soon if the situation continues. Smaller drug manufacturers, in particular, are finding it hard to absorb these costs due to already thin profit margins, raising the risk of reduced production or supply disruptions.

The medicine prices situation is also being closely watched by policymakers, as any sharp increase could affect access to essential drugs for millions. If the conflict persists, the combined impact of higher input costs and supply chain disruptions could lead to noticeable price hikes and potential shortages in the near future.